DBDerek L. Buhl

Derek L. Buhl

*This is an algorithmically generated author record based on publicly available information.

Derek L. Buhl has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An actigraphy-based algorithm to assess daytime napping in people with narcolepsy type 1

    by Raul Torres, Rahul Ghosal, Melissa Naylor, Simerpal K Gill, Yelena Pyatkevich, Sarah L Bermingham, Derek L Buhl, Brian Tracey, Marta Karas, Francesco Onorati, et al.

    Study Objectives: Excessive daytime sleepiness is a defining symptom of narcolepsy, affecting daily functioning and quality of life. We developed and evaluated an actigraphy-based nap detection algorithm to objectively estimate daytime naps, a key manifestation of excessive daytime sleepiness. Materials and Methods: The nap detection algorithm was developed using data from the Multi-Ethnic Study of Atherosclerosis. This dataset included manually annotated naps from 2237 participants with 7 days of wrist-worn actigraphy. The nap detection algorithm was then applied in studies of participants with narcolepsy type 1 (NT1). Results: Our final nap detection algorithm yielded high specificity (Tau B: 93.2%) and accuracy (F1 Area: 83.9%). Applying our algorithm in an observational study (NCT04445129), participants with NT1 experienced 12.8 fewer nap-free days (p < .001) over 28 days and slept 34 minutes more (p < .001) during the day than controls. In a randomized clinical trial (NCT05687903), our algorithm demonstrated that participants with NT1 treated with an orexin receptor 2-selective agonist, oveporexton (TAK-861), experienced 6.1−11.9 additional nap-free days and slept 12−33 minutes fewer versus baseline. Conclusions: Overall, our nap detection algorithm retained sensitivity while minimizing false positives. It reliably identified nap-based phenotypes that differentiate individuals with NT1 from age and sex-matched healthy controls, and it demonstrated that an orexin receptor 2-selective agonist reduces napping in participants with NT1 to normative levels near those of healthy controls.

  • Top Cited Papers
    Open Access

    Biomarker innovations in precision psychiatry diagnostics and treatment strategies

    by Martien J.H. Kas, Kim Q. Do, Michael S. Sand, Rouba Kozak, Elizabeth M. Tunbridge, Maria A. Oquendo, Carol Tamminga, Nikolaos Koutsouleris, Gitte Moos Knudsen, Brenda W.J.H. Penninx, et al.


  • Open Access

    Classification and clustering on nocturnal polysomnography: distinctions and overlaps between central disorders of hypersomnolence

    by Marta Karas, Yishu Gong, Marco Vilela, Emily Schlafly, Francesco Onorati, Alice Cai, Melissa Naylor, Derek L Buhl, Dmitri Volfson, Brian Tracey, et al.

    Study Objectives: Differential diagnosis of narcolepsy type 2 (NT2) from type 1 (NT1) and idiopathic hypersomnia (IH) is challenging due to overlapping symptoms. We developed an automated method using nocturnal polysomnography (nPSG) data to differentiate these conditions and clinical controls (CCs), and explored varying sleep phenotypes within NT1, NT2, IH, and CCs. Methods: We analyzed nPSG data from drug-free individuals with NT1, NT2, and IH, or CCs. Sleep features were derived at whole-night and per-quarter-night levels, including hypnogram, transition probability, hypnodensity, spindle, and quantitative electroencephalogram (qEEG) features. Random forest machine learning models were used for three classification tasks. Within-diagnosis clustering identified potential diagnosis subgroups. Results: The sample included 350 individuals (52% females; median age 30 years; 114 NT1, 90 NT2, 105 IH, and 41 CCs). Our models achieved area under the receiver operating characteristic curve values of 0.87, 0.79, and 0.82 for distinguishing NT2 from CCs, NT2 from IH, and IH from CCs, with corresponding F1 scores of 0.74, 0.71, and 0.69, respectively. qEEG features substantially contributed to model performance, distinguishing NT2 from IH. Cluster analysis revealed two NT1 subgroups (one showing more severe sleep disturbances), two NT2 subgroups (one trended toward NT1, the other toward IH), and two IH subgroups with differences in hypnodensity, qEEG, and spindle characteristics. Conclusions: Our exploratory findings demonstrate strong diagnosis classification performance from nPSG data alone, more easily distinguishing NT2 from CCs than from IH, and IH from CCs. The distinct NT2 subgroups suggest heterogeneity within NT2; further research is warranted to explore these patterns. Statement of Significance Accurate diagnoses of narcolepsy types 2 (NT2) and 1 and idiopathic hypersomnia (IH) remain challenging due to overlapping symptoms. We developed a machine learning model using drug-free nocturnal polysomnography data to automatically differentiate NT2 from clinical controls, NT2 from IH, and IH from clinical controls, with high accuracy. Our model leverages a rich set of sleep features, including spindle and quantitative electroencephalogram (qEEG) metrics. Furthermore, our analysis revealed distinct sleep phenotypes within each diagnosis, suggesting subtypes with varying levels of sleep disturbance and differences at qEEG and spindle levels. These findings provide a novel approach to classifying central disorders of hypersomnolence and suggest disease heterogeneity, which could lead to more accurate and timely diagnoses and personalized treatment strategies.


  • Environmental determinants of ketamine’s prohedonic and antianhedonic efficacy: Persistence of enhanced reward responsiveness is modulated by chronic stress

    by Amaya R. Jenkins, Daniela B. Radl, Thomas J. Kornecook, Diego A. Pizzagalli, Jack Bergman, Derek L. Buhl, Patricio O’DOnnell, Brian D. Kangas


  • Open Access

    Identifying time‐resolved features of nocturnal sleep characteristics of narcolepsy using machine learning

    by Marco Vilela, Brian Tracey, Dmitri Volfson, Lucie Barateau, Alice Cai, Derek L. Buhl, Yves Dauvilliers

    Summary: The differential diagnosis of narcolepsy type 1, a rare, chronic, central disorder of hypersomnolence, is challenging due to overlapping symptoms with other hypersomnolence disorders. While recent years have seen significant growth in our understanding of nocturnal polysomnography narcolepsy type 1 features, there remains a need for improving methods to differentiate narcolepsy type 1 nighttime sleep features from those of individuals without narcolepsy type 1. We aimed to develop a machine learning framework for identifying sleep features to discriminate narcolepsy type 1 from clinical controls, narcolepsy type 2 and idiopathic hypersomnia. The population included polysomnography data from 350 drug‐free individuals (114 narcolepsy type 1, 90 narcolepsy type 2, 105 idiopathic hypersomnia, and 41 clinical controls) collected at the National Reference Centers for Narcolepsy in Montpelier, France. Several sets of nocturnal sleep features were explored, as well as the value of time‐resolving sleep architecture by analysing sleep per quarter‐night. Several patterns of nighttime sleep evolution emerged that differed between narcolepsy type 1, clinical controls, narcolepsy type 2 and idiopathic hypersomnia, with increased nighttime instability observed in patients with narcolepsy type 1. Using machine learning models, we identified rapid eye movement sleep onset as the best single polysomnography feature to distinguish narcolepsy type 1 from controls, narcolepsy type 2 and idiopathic hypersomnia. By combining multiple feature sets capturing different aspects of sleep across quarter‐night periods, we were able to further improve between‐group discrimination and could identify the most discriminative sleep features. Our results highlight salient polysomnography features and the relevance of assessing their time‐dependent changes during sleep that could aid diagnosis and measure the impact of novel therapeutics in future clinical trials.


  • Open Access

    Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers

    by Francis Dijkstra, Patricio O’donnell, Erica Klaassen, Derek Buhl, Mahnaz Asgharnejad, Laura Rosen, Rob Zuiker, Joop van Gerven, Gabriël Jacobs

    TAK-653 is a novel AMPA receptor positive allosteric modulator in clinical development for the treatment of major depressive disorder (MDD). This study aimed to measure the functional pharmacodynamic central nervous system (CNS) effects of TAK-653. A randomised, double-blind, placebo-controlled, three-way crossover (placebo, TAK-653 0.5 mg and 6 mg) study with 24 healthy volunteers was performed. NeuroCart tests consisting of body sway (BS), saccadic peak velocity (SPV), smooth pursuit eye movements (SP), adaptive tracking (AT), Bowdle and Bond and Lader Visual Analogue Scales (B-VAS and BL-VAS) and Stroop test were performed pre-dose and 3.5 and 4 h post-dose. Data were analysed using a mixed model analysis of covariance with baseline as covariate. It was found that TAK-653 did not affect BS and subjective drug effects as measured by B-VAS and BL-VAS at either dose level. TAK-653 0.5 mg increased SPV (degrees/second) (19.49 [5.98, 32.99],P = 0.02) and affected Stroop difference in reaction time between correct congruent and correct incongruent answers and number of correct responses in incongruent trials (22.0 [4.0, 40.0],P = 0.05 and −0.3 [−0.5, −0.1],P = 0.02, respectively). TAK-653 6 mg improved AT (%) (1.68 [0.51, 2.84],P = 0.02) and increased SPV (degrees/s) (15.40 [1.91, 28.90],P = 0.06) and SP (%) (2.32 [0.37, 4.27],P = 0.05). Based on these findings it can be concluded that TAK-653 demonstrated a psychostimulant-like pharmacodynamic profile on the NeuroCart consistent with previously reported increase of cortical excitability following Transcranial Magnetic Stimulation (TMS) of the human motor cortex.


  • Open Access

    Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers

    by Francis Dijkstra, Patricio O'Donnell, Erica Klaassen, Derek Buhl, Mahnaz Asgharnejad, Laura Rosen, Rob Zuiker, Joop van Gerven, Gabriel Jacobs

    TAK-653 is a novel AMPA receptor positive allosteric modulator in clinical development for the treatment of major depressive disorder (MDD). This study aimed to measure the functional pharmacodynamic central nervous system (CNS) effects of TAK-653. A randomised, double-blind, placebo-controlled, three-way crossover (placebo, TAK-653 0.5 mg and 6 mg) study with 24 healthy volunteers was performed. NeuroCart tests consisting of body sway (BS), saccadic peak velocity (SPV), smooth pursuit eye movements (SP), adaptive tracking (AT), Bowdle and Bond and Lader Visual Analogue Scales (B-VAS and BL-VAS) and Stroop test were performed pre-dose and 3.5 and 4 hours post-dose. Data were analysed using a mixed model analysis of covariance with baseline as covariate. It was found that TAK-653 did not affect BS and subjective drug effects as measured by B-VAS and BL-VAS at either dose level. TAK-653 0.5 mg increased SPV (degrees/second) (19.49 [5.98, 32.99], P = 0.02) and affected Stroop difference in reaction time between correct congruent and correct incongruent answers and number of correct responses in incongruent trials (22.0 [4.0, 40.0], P = 0.05 and − 0.3 [− 0.5, − 0.1], P = 0.02, respectively). TAK-653 6 mg improved AT (%) (1.68 [0.51, 2.84], P = 0.02) and increased SPV (degrees/second) (15.40 [1.91, 28.90], P = 0.06) and SP (%) (2.32 [0.37, 4.27], P = 0.05). Based on these findings it can be concluded that TAK-653 demonstrated a psychostimulant-like pharmacodynamic profile on the NeuroCart consistent with previously reported increase of cortical excitability following Transcranial Magnetic Stimulation (TMS) of the human motor cortex.

  • Open Access

    Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation

    by Patricio O’dOnnell, Francis M. Dijkstra, Ugur Damar, Lei Quanhong, Annika A. de Goede, Lin Xu, Andres Pascual-Leone, Derek L. Buhl, Rob Zuiker, Titia Q. Ruijs, et al.

    TAK-653 is a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-positive allosteric modulator being developed as a potential therapeutic for major depressive disorder (MDD). Currently, there are no translational biomarkers that evaluate physiological responses to the activation of glutamatergic brain circuits available. Here, we tested whether noninvasive neurostimulation, specifically single-pulse or paired-pulse motor cortex transcranial magnetic stimulation (spTMS and ppTMS, respectively), coupled with measures of evoked motor response captures the pharmacodynamic effects of TAK-653 in rats and healthy humans. In the rat study, five escalating TAK-653 doses (0.1–50 mg/kg) or vehicle were administered to 31 adult male rats, while measures of cortical excitability were obtained by spTMS coupled with mechanomyography. Twenty additional rats were used to measure brain and plasma TAK-653 concentrations. The human study was conducted in 24 healthy volunteers (23 males, 1 female) to assess the impact on cortical excitability of 0.5 and 6 mg TAK-653 compared with placebo, measured by spTMS and ppTMS coupled with electromyography in a double-blind crossover design. Plasma TAK-653 levels were also measured. TAK-653 increased both the mechanomyographic response to spTMS in rats and the amplitude of motor-evoked potentials in humans at doses yielding similar plasma concentrations. TAK-653 did not affect resting motor threshold or paired-pulse responses in humans. This is the first report of a translational functional biomarker for AMPA receptor potentiation and indicates that TMS may be a useful translational platform to assess the pharmacodynamic profile of glutamate receptor modulators.


  • Open Access

    Schizophrenia-associated SLC39A8 polymorphism is a loss-of-function allele altering glutamate receptor and innate immune signaling

    by Wei Chou Tseng, Veronica Reinhart, Thomas A. Lanz, Mark L. Weber, Jincheng Pang, Kevin Xuong Vinh Le, Robert D. Bell, Patricio O’donnell, Derek L. Buhl

    Schizophrenia is a complex and heterogenous disease that presents with abnormalities in glutamate signaling and altered immune and inflammatory signals. Genome-wide association studies have indicated specific genes and pathways that may contribute to schizophrenia. We assessed the impact of the functional missense variant SLC39A8 (ZIP8)-A391T (ZIP8A391T) on zinc transport, glutamate signaling, and the neuroinflammatory response. The ZIP8A391T mutation resulted in reduced zinc transport into the cell, suggesting a loss in the tight control of zinc in the synaptic cleft. Electrophysiological recordings from perturbed neurons revealed a significant reduction in NMDA- and AMPA-mediated spontaneous EPSCs (sEPSCs) and a reduction in GluN2A and GluA1/2/3 receptor surface expression. All phenotypes were rescued by re-expression of wild-type ZIP8 (ZIP8WT) or application of the membrane-impermeable zinc chelator ZX1. ZIP8 reduction also resulted in decreased BBB integrity, increased IL-6/IL-1β protein expression, and increased NFκB following TNFα stimulation, indicating that ZIP8 loss-of-function may exacerbate immune and inflammatory signals. Together, our findings demonstrate that the A391T missense mutation results in alterations in glutamate and immune function and provide novel therapeutic targets relevant to schizophrenia.


  • Open Access

    Automated Sleep Stage Scoring Using k-Nearest Neighbors Classifier

    by Tamás Kiss, Stephen Morairty, Michael Schwartz, Thomas S.\ Kilduff, Derek L.\ Buhl, Dmitri Volfson